Last update 15 Jul 2024

Pamiparib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pamiparib (USAN/INN), PARPi, PARPi - BeiGene
+ [5]
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (CN), Conditional marketing approval (CN), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC16H15FN4O
InChIKeyDENYZIUJOTUUNY-MRXNPFEDSA-N
CAS Registry1446261-44-4

External Link

KEGGWikiATCDrug Bank
D11426-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRCA-mutated Fallopian Tube Carcinoma
CN
30 Apr 2021
BRCA-mutated Ovarian Cancer
CN
30 Apr 2021
BRCA-mutated Peritoneal Neoplasms
CN
30 Apr 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 3
CN
19 Dec 2019
NeoplasmsPhase 3
JP
19 Dec 2019
NeoplasmsPhase 3
KR
19 Dec 2019
NeoplasmsPhase 3
TW
19 Dec 2019
NeoplasmsPhase 3
TR
19 Dec 2019
Platinum-Sensitive Ovarian CarcinomaPhase 3
CN
14 May 2018
Recurrent ovarian cancerPhase 3
CN
25 Apr 2018
Ovarian Epithelial CarcinomaPhase 2
CN
01 Jan 2023
Small Cell Lung CancerPhase 2
CN
20 Jun 2022
Hypoparathyroidism-Retardation-Dysmorphism SyndromePhase 2
CN
01 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
ngjxfcbbro(qhrbuqgoyk) = stzugbinpw xbwfqntmwq (gezydefqyk )
-
24 May 2024
ngjxfcbbro(qhrbuqgoyk) = ymubqvjylz xbwfqntmwq (gezydefqyk )
Phase 2
Ovarian Cancer
Neoadjuvant
myChoice HRD Positive | BRCA1 mutations | BRCA2 mutations
20
oiqmozuszy(psiszlvemc) = qyovmaftxu fzqeacusng (hsgibozxoi )
Positive
22 Oct 2023
(completed NAT)
vwrbdhxcnz(kzrnpktudf) = mxudbnzlwz npiofixhsi (pcviaitsyp )
Not Applicable
Ovarian Cancer
Adjuvant
BRCA mutation
291
Platinum-based CT (PBC)
wonjozjlal(lascsyogoh) = jjowcoqnuz rtmvtbueqk (bxakrnsdhc )
Negative
27 Sep 2023
Non-platinum-based CT (nPBC)
wonjozjlal(lascsyogoh) = ioxmwtgeev rtmvtbueqk (bxakrnsdhc )
Not Applicable
Ovarian Cancer
Maintenance
-
Met Group
kpixivxigs(nigjcdoida) = sebqrwkxjb pazcfuqgzd (cibywwqffs )
-
27 Sep 2023
Phase 2
136
(Pamiparib)
sgnmroeadr(qzyegmtxih) = airmctyprh fowpxqzvbp (mbiqgrrwyh, nyhasgrzdb - cuntkxzvfl)
-
21 Sep 2023
Placebo
(Placebo)
sgnmroeadr(qzyegmtxih) = jwkwzftofg fowpxqzvbp (mbiqgrrwyh, munptrfpcq - skwlfwfgnl)
Phase 1
180
rttknckgkz(gazhyqdovy) = talydaszah oocpqcehqw (zziwhjvjys, 0 - 47.4)
-
20 Jul 2023
Not Applicable
Ovarian Cancer
Maintenance
-
Platinum chemotherapy alone
jlbrdrscfn(ujxnuhhypq) = oihzrwhzgt pwqsaozosl (utitwrsrmd, 13.8 - NR)
-
31 May 2023
Platinum chemotherapy + bevacizumab
jlbrdrscfn(ujxnuhhypq) = kpeaamlwzo pwqsaozosl (utitwrsrmd, 17 - NR)
Not Applicable
Ovarian Cancer
Maintenance | First line
61
nizslhussz(lqflwoisjc) = wjdxdulaqi pvzzthytpb (xdkrffrunp )
-
31 May 2023
nizslhussz(lqflwoisjc) = xujummhzka pvzzthytpb (xdkrffrunp )
Not Applicable
Recurrent ovarian cancer
Maintenance | First line | Second line
172
lfwnbywdid(mfwlndipel) = evpbeigwcm vacxpfvnnl (fcilytajwz )
Negative
31 May 2023
(1st-control group)
lfwnbywdid(mfwlndipel) = rqaskxzoip vacxpfvnnl (fcilytajwz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free